News tagged with glucagon
DNA variant affects diabetes risk and treatment response
A DNA variant near a digestive enzyme does not only affect risk of developing diabetes but also affects the response to treatment, an international consortium of researchers including the University of Dundee has found.
Diabetes
May 17, 2013 |
not rated yet |
0
|
New treatment may lead the way to fighting obesity and diabetes
Two professors believe they may have a promising lead from which to develop a new treatment for obesity and diabetes.
Overweight and Obesity
Apr 25, 2013 |
not rated yet |
0
Research suggests popular diabetes drugs can cause abnormal pancreatic growth in humans
(Medical Xpress)—Individuals who had taken a type of drug commonly used to treat Type 2 diabetes showed abnormalities in the pancreas, including cell proliferation, that may be associated with an increased risk of neuroendocrine ...
Diabetes
Mar 27, 2013 |
not rated yet |
0
|
Diabetic medication may protect patients from developing heart failure, study finds
A class of medications commonly prescribed to lower blood sugar in diabetic patients appears to protect them from developing heart failure, according to a study at Henry Ford Hospital in Detroit.
Cardiology
Mar 10, 2013 |
not rated yet |
0
High-fat diet impairs satiation signaling in obese-prone
(HealthDay)—Feeding obese-prone rats a high-fat diet leads to impaired satiation signaling through glucagon-like peptide-1 (GLP-1), a gastrointestinal hormone that suppresses food intake and helps regulate ...
Diabetes
Feb 27, 2013 |
not rated yet |
0
Risk of pancreatitis doubles for those taking new class of diabetes drugs
People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those on other forms of sugar-control medication to be hospitalized with pancreatitis, Johns Hopkins researchers report.
Medications
Feb 25, 2013 |
5 / 5 (2) |
1
|
Study suggests glucagon-like peptide-1 receptor agonists related to adolescent weight loss
Preliminary evidence from a clinical trial suggests that treatment with glucagon-like peptide-1 (GLP-1) receptor agonists was associated with reduced body mass index and body weight in adolescents with severe obesity, according ...
Pediatrics
Feb 04, 2013 |
not rated yet |
0
Bile acid sequestrant reduces glucose concentration in T2DM
(HealthDay)—For patients with type 2 diabetes taking metformin monotherapy, the bile acid sequestrant colesevelam reduces fasting and postprandial glucose concentrations without any effects on insulin concentration, ...
Diabetes
Jan 30, 2013 |
5 / 5 (1) |
0
Study: Most-used diabetes drug works in different way than previously thought
A team, led by senior author Morris J. Birnbaum, MD, PhD, the Willard and Rhoda Ware Professor of Medicine, with the Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University ...
Diabetes
Jan 06, 2013 |
5 / 5 (3) |
0
|
Teduglutide seems effective, safe for short bowel syndrome
(HealthDay)—For patients with short bowel syndrome with intestinal failure (SBS-IF), the glucagon-like peptide 2 analogue teduglutide appears to be safe and reduces the number of days off parenteral support, ...
Diseases, Conditions, Syndromes
Dec 12, 2012 |
not rated yet |
0
New findings on glucagon synthesis
Researchers at Karolinska Institutet in Sweden have shown that the cells that produce glucagon are stimulated by the hormone itself. A previous study by the same group demonstrated that this principle also applies to insulin. ...
Medical research
Dec 03, 2012 |
5 / 5 (2) |
0
|
Doubling down against diabetes: Turbo-charged gut hormones
A collaboration between scientists in Munich, Germany and Bloomington, USA may have overcome one of the major challenges drug makers have struggled with for years: Delivering powerful nuclear hormones to specific tissues, ...
Medical research
Nov 13, 2012 |
5 / 5 (2) |
0
|
Joslin researchers gain new understanding of diabetes and kidney disease
Scientists at Joslin Diabetes Center have identified biological mechanisms by which glucagon-like peptide-1 (GLP-1), a gut hormone, protects against kidney disease, and also mechanisms that inhibit its actions in diabetes. ...
Diseases, Conditions, Syndromes
Jul 23, 2012 |
5 / 5 (1) |
0
Physical activity needed in order to reap benefits of dietary restriction
Fruit flies on dietary restriction (DR) need to be physically active in order to get the lifespan extending benefits that come from their Spartan diet. If the same axiom holds true in humans, those practicing caloric restriction ...
Medical research
Jul 02, 2012 |
not rated yet |
0
Absolute incretin effect reduced in type 2 diabetes
(HealthDay) -- For patients with type 2 diabetes mellitus (T2DM) the absolute incretin effect is reduced compared with healthy individuals, but its relative importance is increased, particularly in first-phase ...
Diabetes
Jun 25, 2012 |
5 / 5 (1) |
0
Glucagon
Glucagon, a hormone secreted by the pancreas, raises blood glucose levels. Its effect is opposite that of insulin, which lowers blood glucose levels. The pancreas releases glucagon when blood sugar (glucose) levels fall too low. Glucagon causes the liver to convert stored glycogen into glucose, which is released into the bloodstream. High blood glucose levels stimulate the release of insulin. Insulin allows glucose to be taken up and used by insulin-dependent tissues. Thus, glucagon and insulin are part of a feedback system that keeps blood glucose levels at a stable level. Glucagon belongs to a family of several other related hormones.
For more information about Glucagon, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
